Fox Run Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$294K Buy
+14,556
New +$294K 0.05% 680
2025
Q3
Sell
-21,199
Closed -$487K 892
2025
Q2
$487K Buy
+21,199
New +$526K 0.08% 477
2025
Q1
Sell
-18,526
Closed -$688K 894
2024
Q4
$688K Buy
+18,526
New +$847K 0.12% 317
2024
Q3
Sell
-6,487
Closed -$259K 780
2024
Q2
$259K Sell
6,487
-1,202
-16% -$49.8K 0.05% 590
2024
Q1
$338K Buy
+7,689
New +$397K 0.07% 497
2017
Q1
Sell
-12,600
Closed -$232K 558
2016
Q4
$232K Buy
+12,600
New +$245K 0.12% 388

Other funds holding AMPH

Fox Run Management's AMPH Position: Q2 2026 in Review

Fox Run Management opened a new position in Amphastar Pharmaceuticals (AMPH) in Q2 2026: 14,556 shares worth $294K. The stake represents 0.05% of the portfolio and ranks #680 among its holdings. This is a return to the name: Fox Run Management previously reported a position in AMPH as recently as Q2 2025.

Fox Run Management first reported a position in AMPH in Q4 2016 and has held it in 6 quarters since. The position peaked at $688K in Q4 2024. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Fox Run Management held 14,556 shares of Amphastar Pharmaceuticals worth $294K as of Q2 2026.
  • Amphastar Pharmaceuticals was a new Fox Run Management position in Q2 2026.
  • Amphastar Pharmaceuticals made up 0.05% of Fox Run Management's portfolio in Q2 2026, its #680 holding.
  • Fox Run Management first reported a position in Amphastar Pharmaceuticals in Q4 2016 and has held it in 6 quarters since.
  • Fox Run Management's Amphastar Pharmaceuticals position peaked at $688K in Q4 2024.
  • 212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.